Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors

被引：460

作者：

Liao, Jeffrey Jie-Lou

机构：

[1] TransTech Pharma, High Point, NC 27265 USA

[2] Duke Univ, Dept Chem, Durham, NC 27708 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2007年 / 50卷 / 03期

关键词：

GROWTH-FACTOR RECEPTOR; CYCLIN-DEPENDENT KINASE; STRUCTURE-GUIDED DESIGN; ABL TYROSINE KINASE; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; ANTITUMOR-ACTIVITY; DRUG DISCOVERY; AURORA KINASE; MAP KINASE;

D O I：

10.1021/jm0608107

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

[No abstract available]

引用

页码：409 / 424

页数：16

共 133 条

[51] Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors [J].

Harris, PA ;

Cheung, M ;

Hunter, RN ;

Brown, ML ;

Veal, JM ;

Nolte, RT ;

Wang, LP ;

Liu, W ;

Crosby, RM ;

Johnson, JH ;

Epperly, AH ;

Kumar, R ;

Luttrell, DK ;

Stafford, JA .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (05) :1610-1619

[52] SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors [J].

Heron, NM ;

Anderson, M ;

Blowers, DP ;

Breed, J ;

Eden, JM ;

Green, S ;

Hill, GB ;

Johnson, T ;

Jung, FH ;

McMiken, HHJ ;

Mortlock, AA ;

Pannifer, AD ;

Pauptit, RA ;

Pink, J ;

Roberts, NJ ;

Rowsell, S .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (05) :1320-1323

[53]

HIROSHI H, 2005, CURR TOP MED CHEM, V5, P167

[54] CRYSTAL-STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN-RECEPTOR [J].

HUBBARD, SR ;

WEI, L ;

ELIS, L ;

HENDRICKSON, WA .

NATURE, 1994, 372 (6508) :746-754

[55] The conformational plasticity of protein kinases [J].

Huse, M ;

Kuriyan, J .

CELL, 2002, 109 (03) :275-282

[56] The structure of dimeric ROCK I reveals the mechanism for ligand selectivity [J].

Jacobs, M ;

Hayakawa, K ;

Swenson, L ;

Bellon, S ;

Fleming, M ;

Taslimi, P ;

Doran, J .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (01) :260-268

[57] Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002 [J].

Jacobs, MD ;

Black, J ;

Futer, O ;

Swenson, L ;

Hare, B ;

Fleming, M ;

Saxena, K .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (14) :13728-13734

[58] From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors [J].

Jautelat, R ;

Brumby, T ;

Schäfer, M ;

Briem, H ;

Eisenbrand, G ;

Schwahn, S ;

Krüger, M ;

Lücking, U ;

Prien, O ;

Siemeister, G .

CHEMBIOCHEM, 2005, 6 (03) :531-540

[59] Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors [J].

Jung, FH ;

Pasquet, G ;

Lambert-van der Brempt, C ;

Lohmann, JJM ;

Warin, N ;

Renaud, F ;

Germain, H ;

De Savi, C ;

Roberts, N ;

Johnson, T ;

Dousson, C ;

Hill, GB ;

Mortlock, AA ;

Heron, N ;

Wilkinson, RW ;

Wedge, SR ;

Heaton, SP ;

Odedra, R ;

Keen, NJ ;

Green, S ;

Brown, E ;

Thompson, K ;

Brightwell, S .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (03) :955-970

[60] Signal transduction therapy with rationally designed kinase inhibitors [J].

Keri, Gyoergy ;

Orfi, Laszlo ;

Eros, Daniel ;

Hegymegi-Barakonyi, Balint ;

Szantai-Kis, Csaba ;

Horvath, Zoltan ;

Waczek, Frigyes ;

Marosfalvi, Jeno ;

Szabadkai, Istvan ;

Pato, Janos ;

Greff, Zoltan ;

Hafenbradl, Doris ;

Daub, Henrik ;

Mueller, Gerhard ;

Klebl, Bert ;

Ullrich, Axel .

CURRENT SIGNAL TRANSDUCTION THERAPY, 2006, 1 (01) :67-95

← 1 2 3 4 5 6 7 8 9 10 →